February 28, 2017

Cook Launches 140-mm Zilver PTX Stent in Europe

March 1, 2017—Cook Medical announced the launch of the 140-mm Zilver PTX paclitaxel-eluting stent in Europe. The addition to the company's Zilver PTX product portfolio allows for the treatment of longer lesions with just one stent. The device is deployed via a thumbwheel delivery system.

The Zilver PTX drug-eluting stent is indicated for the treatment of superficial femoral artery disease and has been demonstrated to reduce restenosis and reinterventions by approximately 50% over 5 years compared to Cook's Zilver bare-metal stents and percutaneous transluminal angioplasty.

In March 2016, the 5-year results of the Zilver PTX randomized controlled trial were published by Michael D. Dake, MD, et al online ahead of print in Circulation. The clinical trial confirmed long-term patency for patients treated with the Zilver PTX for peripheral artery disease in femoropopliteal arteries.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

February 28, 2017

Cook Launches 140-mm Zilver PTX Stent in Europe

Current Issue

Keep In Touch